19
Oct

Boehringer Ingelheim joins The Leukemia & Lymphoma Society (LLS) in trial program

Boehringer Ingelheim announced that it will be joining The Leukemia & Lymphoma Society (LLS) in a first-of-its kind collaborative trial program to advance treatments for patients with acute myeloid leukemia (AML).

Read Press Release Here >>